Elizabeth A Donley

US Patent:

20110312019, Dec 22, 2011

Filed:

Mar 22, 2011

Appl. No.:

13/069326

Inventors:

Paul R. WEST - Arena WI, US
Alan M. SMITH - Madison WI, US
Elizabeth L.R. DONLEY - Madison WI, US
Gabriela G. CEZAR - Madison WI, US

Assignee:

Stemina Biomarker Discovery, Inc. - Madison WI

International Classification:

C12Q 1/18

US Classification:

435 32

Abstract:

The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

US Patent:

20200348319, Nov 5, 2020

Filed:

Jan 29, 2019

Appl. No.:

16/961995

Inventors:

- Madison WI, US
Joseph King - Madison WI, US
Paul R. West - Arena WI, US
Michael Ludwig - Middleton WI, US
Elizabeth L.R. Donley - Madison WI, US
Robert Burrier - Verona WI, US

International Classification:

G01N 33/68

Abstract:

The invention provides methods of diagnosing autism spectrum disorders (ASD) by analyzing ratios of concentrations of selected amine containing compounds in a sample, such as a blood sample, from a subject. Based on the discovery that specific amine containing compounds and their ratios are dysregulated in patients with ASD, these metabotypes or subtypes of metabolism have the potential to diagnose earlier and suggest more precise treatment based on the metabolism of the individual. The invention provides methods of analyzing amine containing compounds and ratios in a test subject and determining whether the test subject has or is at risk of developing an ASD by comparing ratios from the test subject to ratios from subjects diagnosed with a neurodevelopmental disorder such as ASD who share a common profile of metabolism which is not found in the majority of typically developing subjects. The invention also provides methods of determining a course of treatment for an individual that has or is at risk of developing an ASD based on the individuals metabotype.

US Patent:

20190178900, Jun 13, 2019

Filed:

May 12, 2017

Appl. No.:

16/301044

Inventors:

Paul West - Arena WI, US
Robert Burrier - Verona WI, US
Joseph King - Madison WI, US
Roxana Alexandridis - Madison WI, US
Laura Egnash - Deforest WI, US
Elizabeth L.R. Donley - Madison WI, US
Michael Ludwig - Middleton WI, US

Assignee:

Stemina Biomarker Discovery, Inc. - Madison WI

International Classification:

G01N 33/68
G01N 30/72

Abstract:

With the present invention, metabolomics biomarkers are used to identify subtypes within the autism spectrum disorder (ASD) population. In one embodiment, levels of the metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) of about six times or greater than the median level in typically developing (TD) individuals or about 2 μM or greater place the individual in an autism subpopulation that includes less than 20% of the total ASD population. Thus, CMPF is a biomarker able to discriminate a subtype of ASD.

US Patent:

20140273069, Sep 18, 2014

Filed:

Apr 21, 2014

Appl. No.:

14/257299

Inventors:

- Madison WI, US
Alan M. Smith - Madison WI, US
Elizabeth L.R. Donley - Madison WI, US
Gabriela G. Cezar - Madison WI, US

Assignee:

STEMINA BIOMARKER DISCOVERY, INC. - Madison WI

International Classification:

G01N 33/50

US Classification:

435 29

Abstract:

The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.